163 related articles for article (PubMed ID: 23798432)
1. Molecular circuit involving KLK4 integrates androgen and mTOR signaling in prostate cancer.
Jin Y; Qu S; Tesikova M; Wang L; Kristian A; Mælandsmo GM; Kong H; Zhang T; Jerónimo C; Teixeira MR; Yuca E; Tekedereli I; Gorgulu K; Alpay N; Sood AK; Lopez-Berestein G; Danielsen HE; Ozpolat B; Saatcioglu F
Proc Natl Acad Sci U S A; 2013 Jul; 110(28):E2572-81. PubMed ID: 23798432
[TBL] [Abstract][Full Text] [Related]
2. Brassinin induces apoptosis in PC-3 human prostate cancer cells through the suppression of PI3K/Akt/mTOR/S6K1 signaling cascades.
Kim SM; Park JH; Kim KD; Nam D; Shim BS; Kim SH; Ahn KS; Choi SH; Ahn KS
Phytother Res; 2014 Mar; 28(3):423-31. PubMed ID: 23686889
[TBL] [Abstract][Full Text] [Related]
3. PI3K-AKT-mTOR pathway is dominant over androgen receptor signaling in prostate cancer cells.
Kaarbø M; Mikkelsen OL; Malerød L; Qu S; Lobert VH; Akgul G; Halvorsen T; Maelandsmo GM; Saatcioglu F
Cell Oncol; 2010; 32(1-2):11-27. PubMed ID: 20203370
[TBL] [Abstract][Full Text] [Related]
4. Nuclear mTOR acts as a transcriptional integrator of the androgen signaling pathway in prostate cancer.
Audet-Walsh É; Dufour CR; Yee T; Zouanat FZ; Yan M; Kalloghlian G; Vernier M; Caron M; Bourque G; Scarlata E; Hamel L; Brimo F; Aprikian AG; Lapointe J; Chevalier S; Giguère V
Genes Dev; 2017 Jun; 31(12):1228-1242. PubMed ID: 28724614
[TBL] [Abstract][Full Text] [Related]
5. mTOR is a fine tuning molecule in CDK inhibitors-induced distinct cell death mechanisms via PI3K/AKT/mTOR signaling axis in prostate cancer cells.
Berrak O; Arisan ED; Obakan-Yerlikaya P; Coker-Gürkan A; Palavan-Unsal N
Apoptosis; 2016 Oct; 21(10):1158-78. PubMed ID: 27484210
[TBL] [Abstract][Full Text] [Related]
6. Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation.
Ghosh PM; Malik SN; Bedolla RG; Wang Y; Mikhailova M; Prihoda TJ; Troyer DA; Kreisberg JI
Endocr Relat Cancer; 2005 Mar; 12(1):119-34. PubMed ID: 15788644
[TBL] [Abstract][Full Text] [Related]
7. Androgens induce prostate cancer cell proliferation through mammalian target of rapamycin activation and post-transcriptional increases in cyclin D proteins.
Xu Y; Chen SY; Ross KN; Balk SP
Cancer Res; 2006 Aug; 66(15):7783-92. PubMed ID: 16885382
[TBL] [Abstract][Full Text] [Related]
8. Reciprocal feedback inhibition of the androgen receptor and PI3K as a novel therapy for castrate-sensitive and -resistant prostate cancer.
Qi W; Morales C; Cooke LS; Johnson B; Somer B; Mahadevan D
Oncotarget; 2015 Dec; 6(39):41976-87. PubMed ID: 26506516
[TBL] [Abstract][Full Text] [Related]
9. Regulation of androgen receptor transcriptional activity by rapamycin in prostate cancer cell proliferation and survival.
Wang Y; Mikhailova M; Bose S; Pan CX; deVere White RW; Ghosh PM
Oncogene; 2008 Nov; 27(56):7106-17. PubMed ID: 18776922
[TBL] [Abstract][Full Text] [Related]
10. DNA-PK, Nuclear mTOR, and the Androgen Pathway in Prostate Cancer.
Giguère V
Trends Cancer; 2020 Apr; 6(4):337-347. PubMed ID: 32209447
[TBL] [Abstract][Full Text] [Related]
11. Androgen receptor-mTOR crosstalk is regulated by testosterone availability: implication for prostate cancer cell survival.
Wu Y; Chhipa RR; Cheng J; Zhang H; Mohler JL; Ip C
Anticancer Res; 2010 Oct; 30(10):3895-901. PubMed ID: 21036700
[TBL] [Abstract][Full Text] [Related]
12. SREBF1 Activity Is Regulated by an AR/mTOR Nuclear Axis in Prostate Cancer.
Audet-Walsh É; Vernier M; Yee T; Laflamme C; Li S; Chen Y; Giguère V
Mol Cancer Res; 2018 Sep; 16(9):1396-1405. PubMed ID: 29784665
[TBL] [Abstract][Full Text] [Related]
13. Canonical and Nuclear mTOR Specify Distinct Transcriptional Programs in Androgen-Dependent Prostate Cancer Cells.
Chen Y; Han L; Dufour CR; Alfonso A; Giguère V
Mol Cancer Res; 2024 Feb; 22(2):113-124. PubMed ID: 37889103
[TBL] [Abstract][Full Text] [Related]
14. Unique targeting of androgen-dependent and -independent AR signaling in prostate cancer to overcome androgen resistance.
Lim SC; Jansson PJ; Assinder SJ; Maleki S; Richardson DR; Kovacevic Z
FASEB J; 2020 Sep; 34(9):11511-11528. PubMed ID: 32713076
[TBL] [Abstract][Full Text] [Related]
15. Direct progesterone receptor and indirect androgen receptor interactions with the kallikrein-related peptidase 4 gene promoter in breast and prostate cancer.
Lai J; Myers SA; Lawrence MG; Odorico DM; Clements JA
Mol Cancer Res; 2009 Jan; 7(1):129-41. PubMed ID: 19147544
[TBL] [Abstract][Full Text] [Related]
16. Androgen receptor remains critical for cell-cycle progression in androgen-independent CWR22 prostate cancer cells.
Yuan X; Li T; Wang H; Zhang T; Barua M; Borgesi RA; Bubley GJ; Lu ML; Balk SP
Am J Pathol; 2006 Aug; 169(2):682-96. PubMed ID: 16877366
[TBL] [Abstract][Full Text] [Related]
17. Nemo-like kinase induces apoptosis and inhibits androgen receptor signaling in prostate cancer cells.
Emami KH; Brown LG; Pitts TE; Sun X; Vessella RL; Corey E
Prostate; 2009 Oct; 69(14):1481-92. PubMed ID: 19514049
[TBL] [Abstract][Full Text] [Related]
18. MIIP inhibits the growth of prostate cancer via interaction with PP1α and negative modulation of AKT signaling.
Yan G; Ru Y; Yan F; Xiong X; Hu W; Pan T; Sun J; Zhang C; Wang Q; Li X
Cell Commun Signal; 2019 May; 17(1):44. PubMed ID: 31092266
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of androgen receptor transactivation function by adenovirus type 12 E1A undermines prostate cancer cell survival.
Li D; Tian G; Wang J; Zhao LY; Co O; Underill ZC; Mymryk JS; Claessens F; Dehm SM; Daaka Y; Liao D
Prostate; 2018 Nov; 78(15):1140-1156. PubMed ID: 30009471
[TBL] [Abstract][Full Text] [Related]
20. Cotargeting Androgen Receptor Splice Variants and mTOR Signaling Pathway for the Treatment of Castration-Resistant Prostate Cancer.
Kato M; Banuelos CA; Imamura Y; Leung JK; Caley DP; Wang J; Mawji NR; Sadar MD
Clin Cancer Res; 2016 Jun; 22(11):2744-54. PubMed ID: 26712685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
